RankingsPricing
  1. JP-listed companies
  2. TAKARA BIO INC.
  3. Financials
  4. Cash and cash equivalents

TAKARA BIO INC.JP:4974

Market cap
¥94.8B
P/E ratio
-10.5x
SummaryFinancialsHistoryOwnershipWorkforce
Period EndCash and cash equivalents (Million JPY)YoY (%)
Mar 31, 202529,549-16.57%
Mar 31, 202435,416-31.69%
Mar 31, 202351,847+119.38%
Mar 31, 202223,633-9.08%
Mar 31, 202125,993+42.30%
Mar 31, 202018,266+7.24%
Mar 31, 201917,033-2.87%
Mar 31, 201817,537-37.54%
Mar 31, 201728,078+44.85%
Mar 31, 201619,384-5.83%
Mar 31, 201520,584

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)